Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

Core Insights - Exagen Inc. reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.13, representing an earnings surprise of -46.15% [1] - The company achieved revenues of $17.24 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.55% and showing a year-over-year increase from $12.51 million [2] - Exagen shares have increased approximately 188.5% year-to-date, significantly outperforming the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Exagen has surpassed consensus revenue estimates four times, but only exceeded EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $18.03 million, and for the current fiscal year, it is -$0.66 on revenues of $67.65 million [7] Industry Context - The Medical - Products industry, to which Exagen belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Exagen's stock may be influenced by the overall outlook of the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] Future Outlook - The sustainability of Exagen's stock price movement will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The estimate revisions trend for Exagen was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]